Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19
Wioleta M. Zelek, Jade Cole, Mark Ponsford, R. A. Harrison, Benjamin E. Schroeder, Nicholas J.A. Webb, Stephen Jolles, Chris Fegan, Matt Morgan, Matt P. Wise, B. Paul Morgan
Abstract
h e r , M o r g a n, M a t t , Wis e, M a t t P. a n d M o r g a n , B. P a ul 2 0 2 0. Co m pl e m e n t in hi bi tio n wi t h t h e C 5 bloc k e r LFG 3 1 6 in s e v e r e COVID-1 9. Am e ri c a n Jou r n al of R e s pi r a t o ry a n d C ritic al C a r e M e di ci n e 2 0 2 (9) , p p . 1 3 0 4-1 3 0 8. 1 0.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Complement (music)BetacoronavirusCoronavirus InfectionsComplement component 5Complement systemVirologyIntensive care medicineImmunologyInternal medicineAntibodyGeneticsInfectious disease (medical specialty)PhenotypeDiseaseOutbreakComplementationBiologyGeneComplement system in diseasesImmune Cell Function and InteractionCOVID-19 Clinical Research Studies